Survodutide
BI 456906 · GLP-1/glucagon dual agonist BI
Boehringer/Zealand GLP-1/glucagon dual agonist (BI 456906). Phase 2/3. Not an approved US obesity pen on this catalog date. Not a DIY MASH protocol.
Use-case scores
0–10 against the evidence we have, not a gym ranking. Hidden domains do not apply here.
- Metabolic / weight7.5/10
Phase 2 obesity plus MASH-adjacent program, Phase 3 underway. Ceiling 8 for Phase 2–3; haircut because no US label and a cake is not SYNCHRONIZE material.
Compound card
- Sequence
- Acyl-modified GLP-1/glucagon dual agonist (BI 456906)
- Class
- Once-weekly dual agonist (Boehringer / Zealand; not FDA-approved as of this review)
- Formula
- Acyl-modified GCGr/GLP-1R dual peptide
- Status
- Not FDA-approved · research use
How it works
Survodutide (BI 456906) is a dual glucagon/GLP-1 receptor agonist (GCGr/GLP-1R) developed by Boehringer Ingelheim and Zealand Pharma. It uses a higher glucagon-to-GLP-1 activity ratio than pemvidutide or mazdutide - with a design optimized for maximizing energy expenditure via glucagon receptor activity while retaining GLP-1-mediated appetite suppression and insulin modulation. Phase 2 MARCH-NASH trial showed significant MASH (metabolic dysfunction-associated steatohepatitis) resolution. Phase 3 obesity trials show up to 18.7% body weight reduction at 6 mg over 46 weeks.
Source: PMID: 38587239 (SYNCHRONIZE Phase 2)
Research Use Cases
- ✓Obesity: High
- ✓MASH (Liver Disease): High
Dosing
| Phase | Dose | Frequency | Notes |
|---|---|---|---|
| Phase 3 Escalation | 0.6 mg → 2.4 mg → 6 mg | Once weekly (SC) | Escalation over 16 weeks. 6 mg is the top studied dose. |
Administration
Timeline
Who it is for
Obesity
HighPhase 3: 18.7% BWL at 6 mg over 46 weeks. Strong candidate for approval.
MASH (Liver Disease)
HighMARCH-NASH Phase 2: 65%+ MASH resolution rate - one of the highest observed for any drug in this indication.
Reconstitution
| Vial | Water | Concentration | Example dose |
|---|---|---|---|
| 4.8 mg research/compounded cake | 2.0 mL BAC | 2.4 mg/mL | 2.4 mg = 1.0 mL = 100 units on a U-100. This is not trial supply. |
Change vial size or water volume? Open the reconstitution calculator.
Safety & Considerations
Investigational - not FDA-approved. Phase 3 obesity and MASH trials ongoing. GI profile consistent with GLP-1 class. Higher glucagon agonism means higher energy expenditure but potential for slightly more cardiovascular effects - monitoring ongoing in trials.
Regulatory & Legal Status
Not currently on the WADA 2026 Prohibited List. Policies may change - verify before competition.
Research Chemical
US Compounding: Not eligible / not available
⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.
Limits of current evidence
- Obesity and MASH programs are not a consumer reconstitution hobby.
- This site will not treat MASH from a peptide page.
- Not interchangeable with pemvidutide or mazdutide.
Verdict
Survodutide is Boehringer/Zealand’s dual GLP-1/glucagon agonist. Phase 2 numbers are large. It is not an approved US obesity pen on this leaf’s date. Do not treat liver-trial language as a DIY MASH protocol.
Interactions & Contraindications
Investigational - not FDA-approved. Phase 3 obesity and MASH trials ongoing. GI profile consistent with GLP-1 class. Higher glucagon agonism means higher energy expenditure but potential for slightly more cardiovascular effects - monitoring ongoing in trials.
Frequently Asked Questions
What makes survodutide different from tirzepatide?▼
Is survodutide FDA-approved?▼
References
- Lautenbach A et al. “"Survodutide for overweight/obesity (Phase 2)".” Nature Medicine (2024).
📚 Related Articles
Looking for a trusted source? See our recommended suppliers
Independently tested · COA-verified · Save 10% with our exclusive code